GSK Flovent/Advair Diskus Needs More COPD Data; Serevent Cleared For COPD

FDA is seeking additional efficacy data on GlaxoSmithKline's Flovent Diskus and Advair Diskus for chronic obstructive pulmonary disease before approving the products for the supplementary indication

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet